MAPK3 and melanoma: The current study focuses on the comparison of the influence of mTOR inhibitor everolimus, and proteins kinase inhibitors: AKT - MK-2206, PI3K - LY294002 and ERK1/2 - U126 and their combinations on the expression of pro-survival proteins: p-Bcl-2 (S70), p-Bcl-2 (T56), Bcl-2, Bcl-xL, and Mcl-1 in metastatic (WM 266–4) and primary (WM 115) melanoma cell lines (Fig. 1).